No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
MindMed Announces New Employee Inducement Grants
MindMed Appoints Matt Wiley as Chief Commercial Officer
'Nevada Senators Take Up Resolution Calling On Congress To Reschedule Psychedelics And Streamline Research' - Marijuana Moment
Mind Medicine's (MNMD) Recent Achievements Boosting Stock
Baird Maintains Mind Medicine(MNMD.US) With Buy Rating, Cuts Target Price to $16
Oppenheimer Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20